What does fear of cancer coming back or progressing feel like?
For many people it is the part of cancer that keeps going after everything else has quietened down.
It can look like checking your body more than you would like to admit. A headache or a sore back gets measured against the worst possible explanation before any ordinary one. The weeks before a scan go strange. Sleep thins out. Plans for next year get made in pencil.
The international consensus definition describes fear of cancer recurrence as "fear, worry, or concern relating to the possibility that cancer will come back or progress" (Lebel et al., 2016). That definition already covers two situations, and they are worth naming separately.
Fear of recurrence is the fear that cancer will come back after treatment has finished and there is no sign of it.
Fear of progression is the fear that cancer which is still there will grow or spread. It belongs to people living with advanced or metastatic cancer, people on ongoing treatment, and people whose cancer has already come back once.
The situations are different. The way the fear works in the mind is much the same. The research on the second situation is thinner, which comes up again below. This page covers both.
Why doesn't my doctor ask about it?
Because follow-up appointments are designed around the body, and this fear sits outside what the appointment is set up to find.
A follow-up appointment has a great deal to get through. Scan results, blood tests, side effects, medications, the plan for the next few months. The fear of the cancer returning is in the room for all of it, often more loudly than anything on the list, but it isn't on the list.
Research with clinicians and services in several countries has described a similar set of barriers. Limited time and heavy workloads. Limited training and confidence in raising the fear and in knowing when to refer. Too few psychologists, and no funded hours for them. And no clear referral pathway, so it isn't obvious who should take it on (Deuning-Smit et al., 2023; Lebel et al., 2025; Smith et al., 2026). In Australia, access to mental health specialists has been described as particularly limited in regional, rural and remote areas (Smith et al., 2026).
Something similar came through at an International Psycho-Oncology Society (IPOS) education session I attended in September, which presented the evaluation of Australian clinician training on fear of cancer recurrence. Clinicians who completed the training felt more knowledgeable and confident straight afterwards, and some of that faded over the following months as they went back to work and met the same practical walls. The barrier that held on most strongly, even after training, was referral. The presenters suggested this may partly reflect how few specialist referral options exist in some rural and remote services (Liu & Smith, 2026). That evaluation was presented at the session rather than in a published paper.
Part of what seems to be going on here is simple.
A question is only easy to ask when the person asking knows what they will do with a yes.
If a clinician asks how frightened you are about the cancer coming back, and you say "very", something has to happen next. If there is no psychologist in the service, no group to refer to, and a waiting list in the nearest city, asking can feel like opening a door with nothing behind it.
That fits with what services themselves report about distress screening more broadly. In an Australian audit of cancer services, the barrier to screening that service representatives named most often was not a lack of tools. It was a lack of resources to act on what screening found (Fradgley et al., 2020).
So the short version is this: fear of cancer coming back or progressing often goes unasked about because it falls between everyone's job, and a question is hard to ask when there is nowhere obvious to send the answer.
None of this means your team doesn't care. Some services do ask, and more are starting to. Australia now has an expert-agreed clinical pathway for this fear (Smith et al., 2024) and free training for clinicians, and hospitals in Melbourne have offered routine screening for it after treatment (Tran et al., 2025). The gap is mostly in the system, not in the goodwill of the people working in it.
Why don't I bring it up myself?
Because there are just as many reasons on your side of the desk.
The appointment feels like it belongs to the medical team, and the fear can feel like a waste of their time. It can feel ungrateful to say you're frightened when the treatment worked, or when the scans are stable. Some people worry that saying it out loud will make it more real, or will be written down somewhere. Some assume it is simply what having had cancer feels like, and that nobody can do anything about it.
Some of these reasons show up in research too. In an Italian study of people screened for distress during cancer treatment, some of those offered a follow-up conversation said they didn't think psychological support would be useful, and some were embarrassed to open up (Meggiolaro et al., 2021).
So the clinician may not be asking, and you may not be saying. Both sides have understandable reasons, and the reasons point the same way.
Isn't everyone scared after cancer? Why would anyone need to ask?
Yes, some fear is expected. That is exactly why it gets overlooked. It's easy to assume that because everyone has some, nobody needs anything for it.
The difference is in how much of your life it is taking up. Fear that rises around scans and settles afterwards is one thing. Fear that sets the agenda for most days, shapes what you plan and how you sleep, and doesn't settle when the results are clear, is something else. From the outside these two can look identical. A person can seem completely fine in a ten-minute appointment while the fear is running their week.
The research gives a sense of the spread. A large analysis pooled individual data from 46 studies, covering more than 11,000 people with cancer across 13 countries. About one in five scored above the cut-off the researchers linked to likely needing specialist help (Luigjes-Huizer et al., 2022). That is a score on a questionnaire, not a diagnosis, and studies focused on this fear may include more people with high fear than the wider population of survivors.
Two other findings from that analysis matter here. People who still had active cancer had similar levels of fear to people who had finished treatment with no sign of cancer. And in that pooled data, people further from diagnosis did not report less fear than people closer to it. It's a snapshot rather than the same people followed over time, but it is one more reason not to assume the fear will have faded on its own, or to guess who is carrying the heavy version without asking.
There is one more trap. Where services do screen, it may be with a general distress measure, such as the Distress Thermometer used in New South Wales' statewide patient-reported measures program. Australian expert consensus has concluded that the Distress Thermometer is not suitable for picking up fear of cancer recurrence (Smith et al., 2024). It's a different thing, and it needs its own question.
There is more on telling ordinary fear from fear that needs attention in How do I know if my fear of cancer coming back is normal?.
Is fear of progression different from fear of recurrence?
The worry works in much the same way. What changes is the situation it sits in.
When you're living with cancer that is still there, the uncertainty isn't hypothetical. Scans are a regular part of life, and treatment decisions may hang on them. That can make it harder, for you and for the people treating you, to tell where a sensible concern ends and the fear running the day begins.
In a large Spanish study of people about to start treatment for advanced cancer, higher fear was linked with being younger, with anxiety and low mood, with uncertainty about the illness, and with a shorter expected survival. It was not linked with the stage or type of cancer (Calderon et al., 2024). A smaller study from the United Kingdom, of people whose cancer had come back, described the fear peaking around scans and appointments (Stewart et al., 2024).
It's worth being honest that the research here is thinner than it is for fear of recurrence. But the gap in asking may be wider. When cancer is ongoing, every appointment has urgent medical business in it, and the fear is easy to leave until next time.
When is it worth raising the fear, even if nobody asks?
If the fear is taking up a real share of your life, it's worth raising, whether or not anyone asks you first.
Some questions you can answer from where you're sitting:
- Is the fear on your mind for a large part of most days?
- Are you checking your body many times a day, or avoiding checks and appointments altogether?
- Is it affecting your sleep, your work, or the plans you are willing to make?
- Has it been like this for more than a few weeks, rather than just around a scan?
- Have you felt down or depressed every day for more than two weeks?
If any of those are a yes, tell your GP or your treating team, and ask about a referral to a psychologist experienced in psycho-oncology. You don't need the right words. Saying you're more frightened about the cancer than you have been letting on is enough to start the conversation. The clinical terms are "fear of cancer recurrence" and "fear of progression", and you can use them if it helps.
Any new or changing physical symptom goes to your treating team as well, whatever is happening with the fear. That is exactly what they are there for.
If you are having thoughts of harming yourself, call Lifeline on 13 11 14 at any time, or 000 in an emergency. If you're outside Australia, contact your local emergency number or crisis line.
Where does this understanding come from?
This article draws on psycho-oncology, the field concerned with the psychological side of cancer, and on the published research on fear of cancer recurrence and progression: studies of how common it is, how it is screened for, and what gets in the way of people receiving help for it. The approaches that inform The Cancer Rollercoaster's work on this fear include metacognitive approaches, which focus on how worry itself works rather than on the content of each fear.
This article is education. It is not therapy, it doesn't replace an individual assessment, and it makes no promise about what will happen to anyone's fear.
Where can I go from here?
If this sounded familiar, Calm After Cancer is my eight-week, self-paced program for the fear of cancer coming back or progressing. It is an evidence-informed educational program, put together from the published research on this fear, and it teaches skills built for worry itself rather than general anxiety techniques. It is for the person whose fear is running the day. It is not therapy, and it isn't the right starting point if you're in crisis.
References
Calderon, C., et al. (2024). Fear of recurrence in advanced cancer patients: Sociodemographic, clinical, and psychological correlates. Cancers, 16(5), 909. https://doi.org/10.3390/cancers16050909
Deuning-Smit, E., Kolsteren, E. E. M., Kwakkenbos, L., Custers, J. A. E., Hermens, R. P. M. G., & Prins, J. B. (2023). Barriers and facilitators for implementation of the SWORD evidence-based psychological intervention for fear of cancer recurrence in three different healthcare settings. Journal of Cancer Survivorship, 17(4), 1057-1071. https://doi.org/10.1007/s11764-022-01285-x
Fradgley, E. A., Byrnes, E., McCarter, K., Rankin, N., Britton, B., Clover, K., Carter, G., Bellamy, D., & Paul, C. L. (2020). A cross-sectional audit of current practices and areas for improvement of distress screening and management in Australian cancer services: Is there a will and a way to improve? Supportive Care in Cancer, 28(1), 249-259. https://doi.org/10.1007/s00520-019-04801-5
Lebel, S., Chu, A., et al. (2025). Investigating the pre-implementation facilitators and barriers of the implementation of the Fear of Recurrence Therapy (FORT) intervention in Canadian cancer centers. Psycho-Oncology, 34(10), e70293. https://doi.org/10.1002/pon.70293
Lebel, S., Ozakinci, G., Humphris, G., Mutsaers, B., Thewes, B., Prins, J., Dinkel, A., & Butow, P. (2016). From normal response to clinical problem: Definition and clinical features of fear of cancer recurrence. Supportive Care in Cancer, 24(8), 3265-3268. https://doi.org/10.1007/s00520-016-3272-5
Liu, J., & Smith, A. B. (2026, September 14). Fear of cancer recurrence: The clinical pathway, the eviQ training module and its evaluation [Webinar]. International Psycho-Oncology Society.
Luigjes-Huizer, Y. L., Tauber, N. M., Humphris, G., Kasparian, N. A., Lam, W. W. T., Lebel, S., Simard, S., Smith, A. B., Zachariae, R., Afiyanti, Y., Bell, K. J. L., Custers, J. A. E., de Wit, N. J., Fisher, P. L., Galica, J., Garland, S. N., Helsper, C. W., Jeppesen, M. M., Liu, J., Mititelu, R., Monninkhof, E. M., Russell, L., Savard, J., Speckens, A. E. M., van Helmondt, S. J., Vatandoust, S., Zdenkowski, N., & van der Lee, M. L. (2022). What is the prevalence of fear of cancer recurrence in cancer survivors and patients? A systematic review and individual participant data meta-analysis. Psycho-Oncology, 31(6), 879-892. https://doi.org/10.1002/pon.5921
Meggiolaro, E., et al. (2021). From distress screening to uptake: An Italian multicenter study of cancer patients. Cancers, 13(15), 3761. https://doi.org/10.3390/cancers13153761
Smith, A. B., Girgis, A., Taylor, N., Pearce, A., Liu, J., Shepherd, H. L., Wu, V. S., Garvey, G., Kirsten, L., Zakhary, I., Ee, C., Ewald, D., Miller, A., & Shaw, J. (2024). Step-by-step: A clinical pathway for stepped care management of fear of cancer recurrence: Results of a three-round online Delphi consensus process with Australian health professionals and researchers. Journal of Cancer Survivorship. https://doi.org/10.1007/s11764-024-01685-1
Smith, B., et al. (2026). Designing for delivery: A Delphi study of feasibility-informed implementation strategies for a fear of cancer recurrence clinical pathway. Supportive Care in Cancer. https://doi.org/10.1007/s00520-026-11275-9
Stewart, R. J., et al. (2024). Fear of progression after cancer recurrence: A mixed methods study. Frontiers in Psychology, 15, 1479540. https://doi.org/10.3389/fpsyg.2024.1479540
Tran, M. J., Jefford, M., Fua, T., Smith, B., et al. (2025). Feasibility and acceptability of the Fear-Less screening and stratified care model. Psycho-Oncology, 34(2), e70070. https://doi.org/10.1002/pon.70070